GH and Insulin Sensitivity
Growth hormone has complex effects on glucose metabolism. GH stimulates the liver to produce IGF-1, which generally improves insulin sensitivity — a positive effect. However, GH also directly promotes glucose production in the liver (gluconeogenesis) and can reduce peripheral insulin sensitivity — a potentially negative effect in diabetic patients. This dual action requires careful monitoring in patients with diabetes or significant insulin resistance.
GH Secretagogues in Diabetic Patients
GH secretagogue protocols (Sermorelin, CJC-1295 + Ipamorelin) are not automatically contraindicated in diabetic patients, but they require more careful baseline assessment and more frequent glucose monitoring during the protocol. Some physicians are comfortable prescribing to well-controlled diabetic patients with appropriate monitoring. Others prefer to avoid GH-axis stimulating compounds in this population.
MOTS-c: A Different Picture
MOTS-c’s research specifically highlights improvements in insulin sensitivity in animal models of metabolic disease. Interestingly, metabolically compromised animals showed more pronounced response than healthy controls. This makes MOTS-c a potentially interesting compound specifically for patients with metabolic dysfunction — though human data is limited.
BPC-157 and Diabetes
BPC-157 does not directly affect the GH or insulin axis and has fewer diabetes-related considerations than GH secretagogues. Recovery protocols using BPC-157 and TB-500 can typically be considered for diabetic patients with appropriate clinical evaluation and monitoring of wound healing response.